145 related articles for article (PubMed ID: 3118374)
1. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
[TBL] [Abstract][Full Text] [Related]
2. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
4. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
[TBL] [Abstract][Full Text] [Related]
5. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
6. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
7. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
[TBL] [Abstract][Full Text] [Related]
10. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Kurokawa T; Iwasa S; Kakinuma A
Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
[TBL] [Abstract][Full Text] [Related]
12. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of a recombinant antibody-targeted plasminogen activator.
Schnee JM; Runge MS; Matsueda GR; Hudson NW; Seidman JG; Haber E; Quertermous T
Proc Natl Acad Sci U S A; 1987 Oct; 84(19):6904-8. PubMed ID: 3116546
[TBL] [Abstract][Full Text] [Related]
14. Antibody-enhanced thrombolysis: capture of tissue plasminogen activator by a bispecific antibody and direct targeting by an antifibrin-tissue plasminogen activator conjugate in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1987; 100():250-5. PubMed ID: 3137708
[No Abstract] [Full Text] [Related]
15. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
Aisina R; Mukhametova L; Varfolomeyev S
Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
[TBL] [Abstract][Full Text] [Related]
16. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
19. A faster-acting and more potent form of tissue plasminogen activator.
Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
[TBL] [Abstract][Full Text] [Related]
20. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
Pannell R; Li S; Gurewich V
J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
